drugset
drugset / Trial / NCT00089388

Cilengitide in Treating Patients With Acute Myeloid Leukemia

NCT00089388 ↗

Phase 2 Terminated 70 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase II trial is studying how well cilengitide works in treating patients with acute myeloid leukemia. Cilengitide may stop the growth of cancer cells by blocking the enzymes necessary for their growth

Timeline

Start
2004-07
Primary completion
2006-06
Completion
—

Outcome

Outcome not reported

Stopped: “Administratively complete.”

Drugs

EvaluationDrugModalityDoseRoute
Subject cilengitide Peptide — Intravenous

Indications

acute basophilic leukemia acute megakaryoblastic leukemia in adult acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with minimal differentiation adult acute monocytic leukemia erythroleukemia